Publication | Open Access
Increased PD-L1 expression in KRAS mutated premalignant human bronchial epithelial cells is enhanced by LKB1 loss and mediated by ERK activation
10
Citations
0
References
2015
Year
Lkb1 LossImmunologyCell DeathImmune SystemCancer BiologyTumor BiologyReceptor Tyrosine KinaseAutophagyTumor ImmunityErk ActivationRadiation OncologyCell SignalingPd-l1 ExpressionMutated KrasMedicineCancer GeneticsKras MutationsCell BiologyLung CancerBronchial NeoplasmImmune Checkpoint InhibitorOncology
Meeting abstracts PD-1/PD-L1 immune checkpoint pathway mediates tumor evasion from the immune system, and may be associated with poor prognosis in lung cancer. Activating KRAS mutations and LKB1 loss are common mutations in non-small cell lung carcinoma (NSCLC). Patients with mutated KRAS